Marina Liu

Marina Liu

Auto-generated profile, based on publicly available information

Marina Liu

University of Saskatchewan College of Medicine

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
RMReza Mirzaei
Reza Mirzaei
CDCharlotte D'MEllo
Charlotte D'MEllo
MLMarina Liu
Marina Liu
ANAna Nikolic
Ana Nikolic
MKMehul Kumar
Mehul Kumar
VYV. Wee Yong
V. Wee Yong
Glioblastomas (GBM) are aggressive brain tumors with extensive intratumoral heterogeneity that contributes to treatment resistance. Spatial characterization of GBMs could provide insights into the role of the brain tumor microenvironment in regulating intratumoral heterogeneity. Here, we performed spatial transcriptomic and single-cell analyses of the mouse and human GBM microenvironment to dissect the impact of distinct anatomical regions of brains on GBM. In a syngeneic GBM mouse model, spatial transcriptomics revealed that numerous extracellular matrix (ECM) molecules, including biglycan, were elevated in areas infiltrated with brain tumor–initiating cells (BTIC). Single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin using sequencing showed that ECM molecules were differentially expressed by GBM cells based on their differentiation and cellular programming phenotypes. Exogeneous biglycan or overexpression of biglycan resulted in a higher proliferation rate of BTICs, which was associated mechanistically with low-density lipoprotein receptor-related protein 6 (LRP6) binding and activation of the Wnt/β-catenin pathway. Biglycan-overexpressing BTICs developed into larger tumors and displayed mesenchymal phenotypes when implanted intracranially in mice. This study points to the spatial heterogeneity of ECM molecules in GBM and suggests that the biglycan–LRP6 axis could be a therapeutic target to curb tumor growth. Significance: Characterization of the spatial heterogeneity of glioblastoma identifies regulators of brain tumor–initiating cells and tumor growth that could serve as candidates for therapeutic interventions to improve the prognosis of patients.

24 November 2025
Verified
Other
Open access
RMReza Mirzaei
Reza Mirzaei
CDCharlotte D'MEllo
Charlotte D'MEllo
MLMarina Liu
Marina Liu
ANAna Nikolic
Ana Nikolic
MKMehul Kumar
Mehul Kumar
VYV. Wee Yong
V. Wee Yong
Glioblastomas (GBM) are aggressive brain tumors with extensive intratumoral heterogeneity that contributes to treatment resistance. Spatial characterization of GBMs could provide insights into the role of the brain tumor microenvironment in regulating intratumoral heterogeneity. Here, we performed spatial transcriptomic and single-cell analyses of the mouse and human GBM microenvironment to dissect the impact of distinct anatomical regions of brains on GBM. In a syngeneic GBM mouse model, spatial transcriptomics revealed that numerous extracellular matrix (ECM) molecules, including biglycan, were elevated in areas infiltrated with brain tumor–initiating cells (BTIC). Single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin using sequencing showed that ECM molecules were differentially expressed by GBM cells based on their differentiation and cellular programming phenotypes. Exogeneous biglycan or overexpression of biglycan resulted in a higher proliferation rate of BTICs, which was associated mechanistically with low-density lipoprotein receptor-related protein 6 (LRP6) binding and activation of the Wnt/β-catenin pathway. Biglycan-overexpressing BTICs developed into larger tumors and displayed mesenchymal phenotypes when implanted intracranially in mice. This study points to the spatial heterogeneity of ECM molecules in GBM and suggests that the biglycan–LRP6 axis could be a therapeutic target to curb tumor growth.Significance:Characterization of the spatial heterogeneity of glioblastoma identifies regulators of brain tumor–initiating cells and tumor growth that could serve as candidates for therapeutic interventions to improve the prognosis of patients.

17 April 2023
Verified
Other
Open access
PDF file
RMReza Mirzaei
Reza Mirzaei
CDCharlotte D'MEllo
Charlotte D'MEllo
MLMarina Liu
Marina Liu
ANAna Nikolic
Ana Nikolic
MKMehul Kumar
Mehul Kumar
VYV. Wee Yong
V. Wee Yong
Additional analysis of in vitro proliferative effects of biglycan.

17 April 2023
Verified
Other
Open access
RMReza Mirzaei
Reza Mirzaei
CDCharlotte D'MEllo
Charlotte D'MEllo
MLMarina Liu
Marina Liu
ANAna Nikolic
Ana Nikolic
MKMehul Kumar
Mehul Kumar
VYV. Wee Yong
V. Wee Yong
Graphical A multi-omics analysis of the glioblastoma tumor microenvironment revealed that biglycan, predominantly expressed by inflammatory BTICs, drives tumor growth. The graphics were generated with Biorender.com.

17 April 2023
Verified
Other
Open access
PDF file
RMReza Mirzaei
Reza Mirzaei
CDCharlotte D'MEllo
Charlotte D'MEllo
MLMarina Liu
Marina Liu
ANAna Nikolic
Ana Nikolic
MKMehul Kumar
Mehul Kumar
VYV. Wee Yong
V. Wee Yong
Quality control analysis of spatial transcriptomics.

15 May 2023
Verified
Other
Open access
PDF file
RMReza Mirzaei
Reza Mirzaei
CDCharlotte D'MEllo
Charlotte D'MEllo
MLMarina Liu
Marina Liu
ANAna Nikolic
Ana Nikolic
MKMehul Kumar
Mehul Kumar
VYV. Wee Yong
V. Wee Yong
Quality control analysis of spatial transcriptomics.